Nasal vaccines show new promise for human papillomavirus (HPV) to address cervical cancer and whooping cough. In business news, Korro’s stock craters 81% as AATD interim Phase I/II results miss expectations. Additionally, Johnson & Johnson acquires Halda to expand their cancer pipeline while Merck acquires Cidara to boost antivirals. Lastly, the inaugural Genetic Agency Technology Conference (GATC) hosted by Dyno Therapeutics brought together a diverse group of researchers, entrepreneurs, and patient advocates to discuss the mission of genetic agency, or an individual’s ability to take action at the genetic level to live a healthier life.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine
GEN, November 15, 2025
Novel Nasal Spray Vaccine for Pertussis Shows Promise
By Corinna Singleman, PhD, GEN, November 12, 2025
StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia
By Alex Philippidis, GENEdge, November 16, 2025
J&J Expands Cancer Pipeline with $3B Halda Acquisition
By Alex Philippidis, GENEdge, November 18, 2025
Merck to Acquire Cidara for $9.2B, Bolstering Antiviral Pipeline
By Alex Philippidis, GEN, November 15, 2025
Top 20 Drugs Heading for the Patent Cliff, 2026-2029
By Alex Philippidis, GEN, November 1, 2025
AI Meets Genetic Agency at Dyno GATC 2025
By Fay Lin, PhD, GENEdge, November 14, 2025
Genetic Agency on Display at GATC 2025
By Kevin Davies, PhD, and Fay Lin, PhD, GEN, November 13, 2025
Dyno GATC Announces AI Agents, Muscle Capsid, and Manufacturing Partner
By Fay Lin, PhD, GEN Edge, November 11, 2025
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD
The post New Nasal Vaccines, Korro Stock Dips, J&J and Merck Acquisitions, and Dyno GATC appeared first on GEN – Genetic Engineering and Biotechnology News.
